Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Services-Misc Health & Allied Services, NEC · market cap $16466.7B · as of 2026-06-23
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| FKS518 | Phase 3 | Postmenopausal Osteoporosis |
| Propofol | Phase 3 | General Anesthesia |
| SmofKabiven extra Nitrogen | Phase 3 | Nutrition Therapy |
| SmofKabiven emulsion for infusion | Phase 3 | Parenteral Nutrition |
| Solution for Peritoneal Dialysis | Phase 3 | Chronic Kidney Failure |
| SMOF lipid and Intralipid | Phase 3 | Parenteral Nutrition |
| Difelikefalin Injection | Phase 3 | Uremic Pruritus |
| Patiromer Powder for Oral Suspension (Part A) | Phase 3 | Hyperkalemia |
| Ketosteril® | Phase 2 | Renal Insufficiency, Chronic |
| MSB11456 | Phase 3 | Rheumatoid Arthritis |
| Osvaren Granules | Phase 3 | Hyperphosphatemia |
| Difelikefalin | Phase 2 | Pruritus |
| MSB11022 | Phase 3 | Moderate to Severe Rheumatoid Arthritis |
| SmofKabiven Peripheral | Phase 3 | Parenteral Feeding |
| 6% hydroxyethyl starch 130/0.4 | Phase 3 | Hypovolemia |
| Humira® | Phase 3 | Psoriasis |
| 1: Hydroxyethyl starch 130/0.4, 6 % | Phase 3 | Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage |
| 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Phase 3 | Sepsis |
| PA21 | Phase 3 | Chronic Kidney Disease Requiring Chronic Dialysis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.
See ProData from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.